- Home
- BMRN vs EICB Comparison
BMRN vs EICB Comparison
Compare BMRN & EICB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRN
- EICB
- Stock Information
- Founded
- BMRN 1996
- EICB N/A
- Country
- BMRN United States
- EICB
- Employees
- BMRN N/A
- EICB N/A
- Industry
- BMRN Biotechnology: Pharmaceutical Preparations
- EICB
- Sector
- BMRN Health Care
- EICB
- Exchange
- BMRN Nasdaq
- EICB Nasdaq
- Market Cap
- BMRN 13.7B
- EICB N/A
- IPO Year
- BMRN 1999
- EICB N/A
- Fundamental
- Price
- BMRN $70.52
- EICB $24.93
- Analyst Decision
- BMRN Buy
- EICB
- Analyst Count
- BMRN 22
- EICB 0
- Target Price
- BMRN $94.00
- EICB N/A
- AVG Volume (30 Days)
- BMRN 1.6M
- EICB N/A
- Earning Date
- BMRN 04-23-2025
- EICB N/A
- Dividend Yield
- BMRN N/A
- EICB N/A
- EPS Growth
- BMRN 153.71
- EICB N/A
- EPS
- BMRN 2.21
- EICB N/A
- Revenue
- BMRN $2,853,915,000.00
- EICB N/A
- Revenue This Year
- BMRN $12.23
- EICB N/A
- Revenue Next Year
- BMRN $9.90
- EICB N/A
- P/E Ratio
- BMRN $31.97
- EICB N/A
- Revenue Growth
- BMRN 17.97
- EICB N/A
- 52 Week Low
- BMRN $60.63
- EICB N/A
- 52 Week High
- BMRN $94.85
- EICB N/A
- Technical
- Relative Strength Index (RSI)
- BMRN 59.12
- EICB 45.02
- Support Level
- BMRN $69.89
- EICB $24.85
- Resistance Level
- BMRN $73.51
- EICB $25.18
- Average True Range (ATR)
- BMRN 2.04
- EICB 0.10
- MACD
- BMRN 0.16
- EICB -0.00
- Stochastic Oscillator
- BMRN 52.81
- EICB 26.07
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
About EICB Eagle Point Income Company Inc. 7.75% Series B Term Preferred Stock Due 2028
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation.